Rare Immunology Target Hansa Biopharma as a partner for immunomodulatory therapies addressing rare IgG-mediated autoimmune conditions and organ transplantation, aligning outreach around their focus on rare immunological diseases.

Commercial-Stage Leverage their transition to commercial-stage operations and recent leadership changes to offer platform collaborations, distribution partnerships, or co-development opportunities that accelerate market access.

Financial Backing With substantial funding and a mid-size revenue footprint, present value propositions that fit their capital planning, such as milestone-based collaborations, scalable manufacturing, and risk-sharing manufacturing agreements.

Strategic Expansions Position BD efforts around upcoming product launches, Phase 3 data discussions, and capital markets activities to align messaging with their investor-focused events and potential sponsor opportunities.

Technology & Ops Offer integrated digital and analytics solutions that complement their tech stack (Power BI, Microsoft 365, ERP/CRM ecosystems) for real-time commercial planning, market access analytics, and patient outcomes tracking.